GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Equity-to-Asset

Innate Pharma (XPAR:IPH) Equity-to-Asset : 0.28 (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Innate Pharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €51.90 Mil. Innate Pharma's Total Assets for the quarter that ended in Dec. 2023 was €184.19 Mil. Therefore, Innate Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.28.

The historical rank and industry rank for Innate Pharma's Equity-to-Asset or its related term are showing as below:

XPAR:IPH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.24   Med: 0.35   Max: 0.82
Current: 0.28

During the past 13 years, the highest Equity to Asset Ratio of Innate Pharma was 0.82. The lowest was 0.24. And the median was 0.35.

XPAR:IPH's Equity-to-Asset is ranked worse than
76.93% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs XPAR:IPH: 0.28

Innate Pharma Equity-to-Asset Historical Data

The historical data trend for Innate Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Equity-to-Asset Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 0.51 0.40 0.26 0.28

Innate Pharma Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.42 0.26 0.29 0.28

Competitive Comparison of Innate Pharma's Equity-to-Asset

For the Biotechnology subindustry, Innate Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Innate Pharma's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Equity-to-Asset falls into.



Innate Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Innate Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=51.901/184.193
=0.28

Innate Pharma's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=51.901/184.193
=0.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innate Pharma  (XPAR:IPH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Innate Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Innate Pharma (XPAR:IPH) Business Description

Traded in Other Exchanges
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others.

Innate Pharma (XPAR:IPH) Headlines

No Headlines